Related by context. All words. (Click for frequent words.) 80 Patient Enrollment 80 NDA Submission 80 Meets Primary Endpoint 79 Phase 2b Clinical Trial 78 Phase 2a Trial 78 Phase IIb Clinical Trial 78 Completes Patient Enrollment 78 Phase IIb Trial 78 Lupus Drug 77 Phase 2a Clinical Trial 77 PDUFA Date 77 Milestone Payment 77 Phase 1b Clinical Trial 77 Receives Orphan Drug Designation 77 Clinical Trial Results 77 Phase III Clinical Trial 77 Drug Candidate 77 FDA Approvals 77 Completes Enrollment 77 Phase 2b Trial 76 Phase III Trial 76 Gout Drug 76 First Patient Enrolled 76 FDA Accepts 76 First Patient Treated 76 Expanded Indication 76 Files IND 76 Prostate Cancer Vaccine 76 Submits NDA 76 Study Evaluating 76 Epilepsy Drug 76 Receives Milestone Payment 75 Initiates Clinical 75 Files Investigational 75 Preclinical Data 75 Migraine Drug 75 Clinical Trial Data 75 Initiates Clinical Trial 75 Receives Approvable Letter 75 Successfully Completes Phase 75 Dose Escalation 75 Milestone Payment From 75 Immunomedics Announces 75 Pivotal Phase III 75 Initiates Enrollment 75 Initiates Phase III 75 RNAi Therapeutics 75 JAK2 Inhibitor 74 Present Preclinical Data 74 Novel Oral 74 Demonstrates Positive 74 Earns Milestone Payment 74 Inhaled Insulin 74 Lung Cancer Drug 74 Single Dose 74 Granted Orphan Drug 74 Shows Promising 74 Pivotal Trial 74 Improves Survival 74 Severe Sepsis 74 Presents Preclinical Data 74 Taro Receives 74 HDAC Inhibitor 74 Oral Fingolimod 73 Investigational Compound 73 Receives Orphan Drug 73 Schizophrenia Drug 73 Osteoporosis Drug 73 Combination Treatment 73 Arthritis Drug 73 Presents Positive 73 Pivotal Clinical Trial 73 Fast Track Status 73 Clinical Trial Evaluating 73 Demonstrates Sustained 73 Initiates Phase II 73 Phase 2b Study 73 Treatment Naïve 73 Metastatic Melanoma 73 Initiate Phase 73 Demonstrates Significant 73 Mylan Receives Approval 73 Prolongs Survival 73 Dose Ranging Study 73 IND Application 73 Generic Version 73 Pharmacokinetic Study 73 Systemic Delivery 73 Phase IIa Clinical Trial 73 Submits Biologics License Application 73 Novel Antibiotic 72 Investigational Treatment 72 Phase III Pivotal 72 Schizophrenia Treatment 72 RNAi Therapeutic 72 Pivotal Study 72 Advanced Melanoma 72 Pivotal Phase 72 Backs FY# View 72 Confirmatory Phase 72 Phase Ib Clinical Trial 72 Drug Fails 72 Hepatitis C Treatment 72 Vaccine Adjuvant 72 First Patient Dosed 72 Combination REOLYSIN R 72 Key Milestones 72 II Clinical Trial 72 Begins Dosing 72 Myeloma Patients 72 Chemotherapy Regimen 72 Fungal Infections 72 Hematological Malignancies 72 Improves Outcomes 72 Regeneron Pharma 72 Psoriasis Drug 72 JAK Inhibitor 72 Oral Calcitonin 72 Nasdaq Deficiency Notice 72 Receives Fast Track 72 Nicotine Vaccine 72 Rheumatoid Arthritis Patients 72 Blood Pressure Drug 72 Clinical Trial Enrollment 72 Initiate Phase III 72 Initiates Clinical Trials 71 Achieves Primary Endpoint 71 Tezampanel 71 Rheumatoid Arthritis Drug 71 Receives CE Marking 71 Cholesterol Lowering Drug 71 Therapeutic Vaccine 71 Immunotherapeutic 71 Pooled Analysis 71 Nuvelo Announces 71 FDA Clears 71 Pulmonary Arterial Hypertension 71 Polymerase Inhibitor 71 Ebola Vaccine 71 Resubmission 71 Nasdaq Delisting Notice 71 Anti Tumor Activity 71 Reaffirms FY# Outlook 71 Antitumor Activity 71 Inhaled Nitric Oxide 71 Anti Tumor 71 Regenerative Cells 71 Phase III Trials 71 Revises FY# Outlook 71 Demonstrates Potent 71 Receive Milestone Payment 71 Reiterates FY# Outlook 71 Patient Enrolment 71 Adjuvant Treatment 71 Clinical Outcome 71 Submits Response 71 Topline Results 71 Cholesterol Drug 71 Collaborators Present 71 Flamel Technologies Announces 71 Biomarker Study 71 HCV Protease Inhibitor 71 rPA Anthrax Vaccine 71 Million Milestone Payment 71 Pivotal Trials 71 Drug Shows Promise 71 Rotavirus Vaccine 71 Prostate Cancer Patients 71 Phase III Clinical Trials 71 Novel Inhibitor 71 Plaque Psoriasis 70 Optimer Pharma 70 Treatment Regimen 70 Therapeutic Antibody 70 Investigational Drug 70 Employment Inducement Awards 70 FDA Approvable Letter 70 Protease Inhibitor 70 Lung Cancer Trial 70 Preclinical Study 70 Gets FDA Clearance 70 Pharmacyclics Announces 70 Alvine Pharmaceuticals 70 Reports Preclinical Data 70 Reaffirms FY# Guidance 70 Controlled Study 70 Kinase Inhibitor 70 Drug Combo 70 Patient Accrual 70 Announce License Agreement 70 Patients Suffering 70 Stent Thrombosis 70 Antiviral Activity 70 Initiates Phase 2b 70 Double Blind Placebo 70 Backs FY# Forecast 70 Transdermal Patch 70 Aethlon Medical Releases 70 Investigational Agent 70 Brentuximab Vedotin SGN 70 Intravenous Formulation 70 Shows Efficacy 70 Anticancer Activity 70 Smallpox Vaccine 70 Clinical Evaluation 70 Patients Enrolled 70 Survival Benefit 70 Commences Phase 70 Miraculins Announces 70 Backs FY# Outlook 70 Dose Ranging 70 Liver Toxicity 70 Osteoporosis Treatment 70 Submits Supplemental 70 Demonstrates Efficacy 70 Neoadjuvant Chemotherapy 70 Announces FDA Clearance 70 Milestone Payments 70 Cervical Cancer Vaccine 70 Topical Treatment 70 Lifts FY# Outlook 70 Anticancer Drug 70 Anti CD# Antibody 70 Disease Progression 70 AVI BioPharma Announces 70 Glufosfamide 70 REG1 Anticoagulation System 70 Sunesis Pharma 69 VIVITROL ® 69 Effectively Treats 69 Testosterone Patch 69 Tyrosine Kinase Inhibitor 69 Chronic Hepatitis C 69 Antibody Drug Conjugate 69 Treatment Reduces 69 Autologous Stem Cell Transplantation 69 Nasdaq Notice Regarding 69 Initiate Clinical Trial 69 Provides Update Regarding 69 Shows Promise Against 69 Nasal Powder 69 Vicriviroc 69 Unfractionated Heparin 69 FDA Clearance 69 NASDAQ Listing Requirements 69 Treatment Experienced 69 Autoimmune Disease 69 Develop Novel 69 Combo Therapy 69 Anti Inflammatory Drug 69 Shingles Vaccine 69 Vaccine Candidate 69 VentiRx Pharmaceuticals 69 Revises FY# Guidance 69 Seasonal Influenza Vaccine 69 FDA Okays 69 Smooth Muscle 69 Completes Dosing 69 Drug Eluting Coronary Stent 69 Generic Versions 69 See CLINICAL PHARMACOLOGY 69 Awarded Qualifying Therapeutic 69 Hematological Cancers 69 Well Tolerated 69 Supplemental Biologics License Application 69 Sapacitabine 69 pralatrexate injection folate analogue 69 Sagent Pharmaceuticals Announces 69 Projected Release Date 69 Receives Complete Response 69 Predict Risk 69 FOLOTYN ® 69 Significantly Improved 69 Inflammatory Disease 69 Regulatory Clearance 69 Anticancer Compound 69 Lifts FY# Guidance 69 STERIS Corporation Announces 69 Randomized Double Blind 69 Stem Cell Treatment 69 Diamyd Medical Diamyd 69 Reveals Positive 69 Initiates Phase 69 Universal Flu Vaccine 69 Initiate Phase II 69 Vertex Pharmaceuticals Announces 69 Initiates Dosing 69 Total Knee Arthroplasty 69 Versus Placebo 69 Teva Provides Update 69 Receives FDA Clearance 69 Data Suggest 69 Announces Tentative Approval 69 Efficacy Trial 69 Investigational Oral 69 Cutaneous T 69 Spectrum Pharmaceuticals Announces 69 Novel Therapies 69 Randomized Clinical Trial 69 Patent Covering 69 Sangamo BioSciences Announces 69 Metastatic Renal Cell Carcinoma 69 TRANSDUR ™ 69 Infected Patients 69 Randomized Phase 69 Small Molecule 69 Acute Heart Failure 69 Pivotal Phase II 69 Therapeutic Competitors Companies 69 Previously Disclosed 69 Testosterone Gel 69 Positive Opinion 69 Licenses Novel 68 Announces Poster Presentations 68 Less Invasive 68 Adjuvanted 68 Metabolic Disorder 68 Oral Mucositis 68 Hormone Refractory Prostate Cancer 68 Erectile Dysfunction Drug 68 Desvenlafaxine Succinate 68 Hsp# Inhibitor 68 Tumor Targeting 68 Potentially Fatal 68 Hedgehog Pathway 68 Clinical Study Shows 68 Recurrent Breast Cancer 68 Novel Protein 68 Aurora Kinase 68 Oral Cladribine 68 Acute Ischemic Stroke 68 Proven Effective 68 Complicated Skin 68 Appears Safe 68 TriCo Bancshares Announces 68 Patients Treated With 68 Improve Survival 68 Long Term Efficacy 68 Idenix Pharma 68 Adjuvant Chemotherapy 68 VIVUS Announces 68 Treatment Naive Patients 68 Merge Healthcare Announces 68 Trial Evaluating 68 Randomized Clinical Trials 68 Oral Laquinimod 68 Malaria Vaccine 68 PRN FDA Approves 68 Diabetic Nephropathy 68 NOVAVAX 68 FDA APPROVES 68 Influenza Vaccine Production 68 Blood Thinner 68 Ridaforolimus 68 Inflammatory Arthritis 68 Newly Diagnosed Multiple Myeloma 68 Poniard Pharmaceuticals Announces 68 Diabetic Foot Ulcer 68 ViRexx Announces 68 Migraine Treatment 68 Pre Cancerous 68 XPEL Announces 68 Treated Patients 68 Monoclonal Antibody 68 Abstract Accepted 68 Underwritten Public 68 BioDelivery Sciences 68 Backs FY# Guidance 68 Novel Antibody 68 Placebo Controlled Trial 68 Begins Shipment 68 Demonstrates Potential 68 Lifts FY# View 68 HER2 Positive Breast Cancer 68 Pneumococcal Vaccine 68 Renal Cell Carcinoma 68 Personalized Immunotherapy 68 Presents Preclinical 68 Hepatocellular Carcinoma 68 Drug Coated Stent 68 Regains NASDAQ 68 Drug Prevents 68 BIOLASE Announces 68 Non Inferiority 68 Lung Cancer Detection 68 Relapsing Multiple Sclerosis 68 Fewer Side Effects 68 Patent Lawsuit Against 68 Previously Treated 68 Dendritic Cells 68 Asthma Treatment 68 Embolic Protection 68 Diabetic Neuropathic Pain 68 Pandemic Influenza Vaccine 68 Gene Variants 68 Jumps Higher 68 Vascular Disrupting Agent 68 NMT Medical Announces 68 Gene Therapy Trial 68 Xcytrin R 68 Enrolls First 68 MKC# MKC# PP 68 Pafuramidine 68 TRANSDUR ® 68 ANADIGICS Announces 67 Tuberculosis Vaccine 67 Begin Clinical Trials 67 Subgroup Analysis 67 Proxy Proposals 67 For Undisclosed Terms 67 Multiple Ascending Dose 67 Experimental Vaccine 67 product platforms AZX# 67 Rotavirus Vaccines 67 Acute Attacks 67 Epilepsy Drugs 67 Clostridium difficile Infection 67 Interferon Gamma 67 Stent Implantation 67 Medicure Announces 67 Venous Thromboembolism 67 BioElectronics Announces 67 Announcement acc 67 Combination Clinical Trial 67 Statistically Significant 67 Molecular Diagnostic Test 67 Pluristem Therapeutics 67 Prophylactic Treatment 67 Tumor Growth 67 Avian Flu Vaccine 67 Kidney Transplant Patients 67 Beta Blocker 67 R lenalidomide 67 Adjunctive Therapy 67 Novel Compound 67 Often Misdiagnosed 67 PPD Declares 67 Announce Collaboration Agreement 67 Generic Version Of 67 Chronic Myeloid Leukemia 67 Mouse Model 67 Study Evaluates 67 Arno Therapeutics 67 Vaccine Adjuvants 67 Shareholder Meeting Date 67 Genetic Mutation 67 Mg Usa 67 Non Invasive Treatment 67 Preclinical Models 67 Antidepressant Treatment 67 Kaydon Corporation Announces 67 FDA Approves Drug 67 Blast Applications BLAP 67 Sirolimus Eluting 67 Knee Osteoarthritis 67 ALN HPN 67 Novel Mechanism 67 Enhanced Version 67 Issued Patent 67 Preterm Labor 67 GATTEX TM 67 Initiated Phase 67 Vitrasert R 67 Pediatric Patients 67 Prostate Cancer Treatment 67 Study Showed 67 Private Equity Financing 67 Antigen Specific 67 PDL BioPharma Announces 67 TB Vaccine 67 Settle Patent Litigation 67 Aeolus Pharmaceuticals Announces 67 Novel Therapeutic 67 Bosutinib 67 Files Patent Application 67 Tumor Response 67 COVIDIEN 67 Acne Drug 67 Prospective Randomized 67 FY# EPS Forecast 67 Stereotaxis Announces 67 Synta Announces 67 Univest Corporation Declares 67 Treating Chronic 67 Heart Stents 67 SPRYCEL ® 67 Cocaine Addiction 67 Delayed Filing 67 Artificial Pancreas 67 Receives NASDAQ 67 Anticancer Agent 67 Efficacy Results 67 MMR Vaccine 67 Phospholipase A2 67 FY# EPS View 67 Heart Transplant Recipients 67 Study Validates 67 Therapeutic Vaccines 67 Aztreonam Lysine 67 Treatment Shows Promise 67 Humanized Anti 67 Glaucoma Treatment 67 Audited Financials 67 Cyclacel Pharmaceuticals 67 Premature Infants 67 Drug Maker 67 Unsolicited Tender Offer 67 Minimally Invasive Treatment 67 Luveniq 67 Sustained Reduction 67 Estrogen Therapy 67 Accelrys Announces 67 Nasdaq Delisting 67 Commercialize Novel 67 Weight Loss Drug 67 TM Drug Eluting 67 Multiple Myeloma Patients 67 Potent Antiviral Activity 67 Regulatory Submissions 67 Collaborators Publish 67 Anti Nausea 67 Hernia Repair 67 Telaprevir VX 67 Corneal Transplant 67 Symptom Relief 67 Stem Cell Procedure 67 Postmenopausal Osteoporosis 67 Therapeutic Competitors companiesandmarkets.com adEgemonye 67 Significantly Reduces 67 Significantly Improves 67 Slow Progression 67 Proves Effective 67 Guidance Quick Facts 67 Patient Outcomes 67 Heartburn Drugs 67 Peginterferon Alfa 2a 67 Mln Share Buyback 67 Terminate Merger Agreement 67 Unsolicited Proposal From 67 Commence Phase 67 Receives Tentative Approval 67 Equity Funds Declare 67 Patent Issuance 67 Eluting Stent 67 Anti Clotting Drug 67 Novel Vaccine 67 Confirms Efficacy 67 Myelodysplastic Syndromes 67 Anemia Drug 67 Metastatic Colorectal Cancer 67 Patent Infringement Litigation 67 TO AVOID PREGNANCY WHILE 67 Receives SFDA Approval 67 Randomized Double blind 67 Colorectal Cancer Patients 67 Enrolling Patients 67 Silicone Breast Implants 67 Seasonal Allergic Rhinitis 66 Dupuytren Contracture 66 Multicenter Randomized 66 Sleep Disturbances 66 Patent Infringement Suit Against 66 Low Dose 66 Surgical Mesh 66 Announce Merger Agreement 66 Hormone Receptor Positive 66 Submits Application 66 Stronger Warnings 66 Newly Identified 66 Achieves Milestone 66 Microwave Ablation System 66 Randomized Phase II 66 Telik Announces 66 Breast Cancer Recurrence 66 Sirolimus Eluting Stent 66 Diabetic Patients 66 Artery Disease 66 Painkiller Abuse 66 Lowers FY# Outlook 66 BioSante Pharmaceuticals Announces 66 FY# Guidance 66 Drug Eluting Stent System 66 Cancer Vaccines 66 Pegloticase 66 Statin Drugs 66 Gene Linked 66 Novel Compounds 66 Vaccine Protects Against 66 Paclitaxel Carboplatin 66 Submits IND 66 ELADUR ™ 66 Male Contraceptive 66 Patients Receiving 66 Measurement Specialties Announces 66 Accelr8 Announces 66 Ovarian Cancer Patients 66 Inflammatory Markers 66 Romiplostim 66 Hypertensive Patients 66 IDEXX Laboratories Announces 66 Soft Tissue Sarcoma 66 Patients Treated 66 Aggressive Prostate Cancer 66 Improved Survival 66 Risk Stratification 66 Cell Transplants 66 Synthetic Peptide 66 Cancer Treatments 66 Refractory Hodgkin Lymphoma 66 Anti Angiogenesis 66 Generic Lovenox 66 Oral Insulin 66 Corautus Genetics 66 Patent Filings 66 Transplant Patients 66 Pharmos Corporation 66 MBRX 66 Crofelemer budesonide foam 66 Antidepressant Drug 66 Randomized Trials 66 Lung Cancers 66 Nasdaq Delisting Notification 66 Showed Significant 66 Guidelines Issued 66 Monotherapy 66 Resistant Hypertension 66 Demonstrated Significant 66 Nasdaq Listing Requirements 66 Naive Patients 66 Aflibercept 66 Therapy Improves 66 oncolytic virus therapies 66 Signaling Pathway 66 Presents Positive Preclinical 66 Secondary Hyperparathyroidism 66 Safinamide 66 Glatiramer Acetate 66 Advanced Renal Cell 66 Enlarged Prostate 66 Evaluate Strategic Alternatives 66 Completes Patient Enrolment 66 Advanced Colorectal Cancer 66 Recommends Approval 66 Antiviral Drugs 66 Endometrial Cancer 66 microRNA Therapeutics 66 Cholesterol Drugs 66 Carotid Stenting 66 Shown Effective 66 Electrical Stimulation 66 Recurrent Glioblastoma 66 Live Attenuated 66 Wizzard Software Announces 66 Genetic Tests 66 Metabasis Therapeutics 66 Laryngeal Cancer 66 Advanced Prostate Cancer 66 Flagship Product 66 Sign Licensing Agreement 66 POSIDUR TM ELADUR TM 66 R MSCRAMM 66 Announces Initiation 66 Significant Improvements 66 Receives Positive Opinion 66 Study Demonstrates 66 FDA Panel Recommends 66 Ischemic Stroke 66 Cardiovascular Disease Risk 66 Statin Therapy 66 NexMed Receives 66 Osteoporosis Drugs 66 Demonstrate Significant 66 Hepatitis B Vaccine 66 Genes Predict 66 CorVel Announces 66 Renal Cancer 66 Phase III Pivotal Trial 66 Upcoming Milestones 66 Treatment Resistant 66 Therapy Reduces 66 MEK Inhibitor 66 NASDAQ Deficiency Notice 66 Silicone Breast Implant 66 Alnylam Pharma 66 Receives Favorable 66 ISSI Announces 66 Antipsychotic Drug 66 Ariad Pharma 66 Bare Metal Stent 66 DOR BioPharma Announces 66 Issues Shareholder 66 Submits Investigational 66 Treat Heart Failure 66 Launches Generic Version 66 Small Molecule Drug 66 Chronic Hepatitis B 66 AnaSpec Introduces 66 Therapeutic Antibodies 66 Clinical Study 66 Oncology Compounds 66 Somaxon Pharma 66 Hythiam Announces 66 Inovio Pharmaceuticals 66 Heart Failure Patients 66 Adjuvant Therapy 66 Begins Clinical Trial 66 Provides Shareholder 66 Hepatic Encephalopathy 66 Bazedoxifene 66 Left Ventricular Hypertrophy 66 Prostate Cancer Diagnosis 66 Transdermal Delivery 66 Nanoemulsion 66 Elagolix 66 Respiratory Distress 66 Preclinical Testing 66 Guides FY# FY# 66 Helps Predict 66 Autoimmune Diseases 66 Gene Variant 66 Balance Sheet Restructuring 66 NYSE Amex Listing 66 Implantable Device 66 HER2 Positive 66 Combination Therapy 66 CHMP Opinion 66 Cancer Vaccine 66 Announces Presentation 66 Bone Marrow Transplants 66 StaphVAX R 66 Drug Resistant 66 Multicenter Phase 66 EVIZON TM 66 Vaccine Trial 66 Remission Maintenance 66 Postmenopausal Women 66 Clinically Tested 66 Recombinant Protein 66 Drug Coated Stents 66 Mitral Valve Repair 66 Left Ventricular 66 Upcoming Deadline 66 Cardiogenic Shock 66 Late Breaker 65 Oral Spray 65 Updates Guidance 65 Orphan Status 65 oral prodrug 65 Lupus Nephritis 65 Interferon Alpha 65 Valve Replacement 65 Serious Infections 65 Newly Diagnosed Patients 65 Announces Licensing Agreement 65 Hedgehog Pathway Inhibitor 65 Bone Metastases 65 SEACOR Holdings Announces 65 PANVAC VF 65 ZEVALIN ® 65 Catheter Ablation 65 ERBITUX cetuximab 65 Liver Transplant Patients 65 Telik logo TELINTRA 65 NASDAQ Delisting Notice 65 Elderly Patients 65 SulphCo Announces 65 Inc. Nasdaq OXGN 65 Tesetaxel 65 TNF Blockers 65 Skin Lesions 65 Pandemic Flu Vaccine 65 Levoleucovorin 65 Reduces Pain 65 Bare Metal Stents 65 Virco Announces 65 Dyloject TM 65 Lowering Blood Pressure 65 Valortim TM 65 k Clearance 65 Dose Finding 65 Recombinant Human 65 Bush Embraces Pause 65 Percutaneous Tibial Nerve Stimulation 65 Meningitis Vaccine 65 Significant Milestones 65 Flu Strains 65 Treating Depression 65 Enzyme Replacement Therapy 65 Zenvia Phase III 65 Antimicrobial Coating 65 Randomized Study 65 AASLD Meeting 65 Contract Signings 65 EntreMed Presents 65 Emerging Therapies 65 lexidronam injection 65 Migraine Pain 65 Endovascular Treatment 65 Therapeutic Potential 65 XTend Medical XMDC 65 Winmark Corporation Announces 65 Faropenem 65 Increased Mortality 65 Dry Powder Inhaler 65 Sinus Infections 65 Stent Restenosis 65 Influenza Vaccine 65 Inhaled Corticosteroids 65 Fast Tracked 65 Previously Untreated 65 Novel Method 65 Platelet Inhibition 65 Multicore Processor 65 Advisers Urge 65 Genetic Mutations 65 Inc Therapeutic Competitors 65 ORLive Presents 65 Genetic Defect 65 CEPHALON 65 Gastric Cancer 65 Momenta Pharmaceuticals MNTA 65 Review Strategic Alternatives 65 Previously Announced Private Placement 65 Indevus Pharma 65 Ercole Biotech 65 Prodarsan R 65 Voluntary Withdrawal 65 Protein Linked 65 Shows Statistically Significant 65 PremierWest Bancorp Announces 65 ENDEAVOR IV 65 Breast Cancer Treatment 65 TKB# 65 Companion Diagnostic 65 #D# #F C 65 Phase IIa Trial 65 Bioartificial Liver 65 motexafin gadolinium Injection 65 ISTODAX ® 65 vapreotide acetate 65 Saehan Bancorp Reports 65 Brain Metastases 65 PRAECIS PHARMACEUTICALS INCORPORATED 65 Interferon Beta 65 Augment ™ 65 Fabry Disease 65 rxRNA 65 Hydrochlorothiazide Tablets 65 Successful Completion 65 Taglich Brothers Initiates Coverage 65 Oral Fluid 65 Altera Ships 65 Node Positive 65 Tablet Formulation 65 Hip Fractures 65 Orally Active 65 TLK# 65 Lymphoma Patients 65 Stent Placement 65 Ephedra Ban 65 Patients Undergoing 65 Eszopiclone 65 Demonstrates Statistically Significant 65 Quarterly Dividend Payment 65 Carotid Artery Stenting 65 WGNB Corp. Announces 65 Gene Variation 65 DNA Methylation 65 Atopic Dermatitis 65 Release Capsules 65 Protein Synthesis 65 Provides Status 65 bronchospasm dizziness headache 65 Forecast Quick Facts 65 Q3 Profit Decreases 65 #nm Process 65 Expedited Review 65 Bradmer Pharmaceuticals 65 Annual Meeting Date 65 Ocrelizumab 65 Mln Stock Buyback 65 Heart Failure Treatment 65 Protein Biomarker 65 Genes Associated 65 Newest Version 65 KB Home Swings 65 Crowflight Announces 65 Gene Mutation 65 Randomized Phase III 65 Ticker Symbol Change 65 Blood Pressure Reduction 65 Myelofibrosis 65 By JENNIFER LEARN 65 Critically Ill Patients 65 Sono Tek Announces 65 GRAS Status 65 Kinase Inhibitors 65 Fracture Risk 65 IN PATIENTS WITH 65 BiTE Antibody 65 Acute Decompensated Heart Failure 65 Interferon beta 1a 65 Poster Presentations 65 Virus Infection 65 Significantly Reduced 65 Magnetic Stimulation 65 Alexion Pharma 65 Chronic Lymphocytic Leukemia 65 Hypercholesterolemia 65 Nanophase Announces 65 Antibody Discovery 65 Salix Pharmaceuticals Announces 65 Arthritis Drugs 65 Fibromyalgia Pain 65 Irvine Sensors Receives 65 Long Term Outcomes 65 By JAMAAL ABDUL 65 Tremendous Growth 65 siRNA Delivery 65 TOFUTTI Announces 65 Receives CE 65 Results Confirm 65 ARIXTRA R 65 Septic Shock 65 Dynasil Announces 65 Hepatitis C Infection 65 Antibiotic Treatment 65 Chronic Sinusitis 65 Brain Scans 65 Vioxx Successor 65 Ozarelix 65 Archexin 65 Receptor Agonist 65 Synalloy Corporation Announces 65 Technological Advances 65 Accelerate Commercialization 65 Ecallantide 65 Clinical Trials Update 65 Host Teleconference 65 Viral Infections 65 Adverse Event 65 Randomized Double Blind Placebo 65 NASDAQ Delisting 65 Major Step Toward 65 liver resection surgeries 65 Vion Pharmaceuticals 65 PROMUS R 65 Reduces Risk 65 Q2 Loss Narrows 65 Iloperidone 65 CFO Resignation 65 Generic Protonix 65 Issues Guidance 65 BIOSCIENCES 65 Horizant ™ 65 Neural Stem Cells 65 Pregnancy Linked 65 Strengthens Balance Sheet 65 Factor Xa Inhibitor 65 Agonist MABA program 65 FDA Approval 65 Transdermal Drug 65 Unsolicited Proposal 65 novel orally inhaled 65 Lung Cancer Survival 65 Pending Acquisition 65 Augment TM 65 Localized Prostate Cancer 65 Listing Compliance 65 Gene Silencing 65 GTC recombinant form 65 Obese Patients 65 Medoro Resources Announces 65 Q4 Profit Decreases 65 Human Monoclonal Antibodies 65 Milestone Achieved 65 Insteel Industries Announces 65 Breast Ultrasound 65 Photovoltaic Module 65 Orthostatic Hypotension 65 Chemotherapeutic Agents 65 Ondansetron Orally Disintegrating Tablets 65 Invoke Fifth Amendment 65 Protein Involved 65 initiated Phase Ib 65 NexgenRx Announces 65 Guides FY# Earnings 65 Aliskiren 65 alfa 2a 65 Overactive Bladder 65 NASH Huntington 65 Cancer Biomarkers 65 Paroxysmal Atrial Fibrillation 65 Receives Notification 65 Successfully Treated 65 Announces Favorable 65 Neutral Analyst Blog 64 TRACON Pharmaceuticals 64 Stent Coating